Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Advanced hybrid closed-loop (AHCL) therapy improves glycemia. However, it is not known if there is an improvement in overall outcomes with AHCL for youth with type 1 diabetes (T1D) at high risk of diabetes-related complications. The study aimed to capture the experiences of youth with suboptimal glycemic control when commencing AHCL therapy in a clinical trial setting.

Methods: This was a singlecenter substudy of a multicenter 6-month randomized clinical trial. Youth between 12 and 25 years of age on insulin pump therapy with HbA1c > 8.5% (> 69 mmol/mol) who commenced AHCL therapy with Medtronic MiniMed™ system were invited to participate in a semistructured interview after 6 months of AHCL. Open-ended questions were used to explore the participants' lived experience of AHCL in improving their glucose levels and its impact on diabetes management and well-being. The interviews were audiorecorded, transcribed, and analyzed using thematic analysis.

Results: Ten youth with T1D with a mean (SD) age of 17.4 (2.9) years, diabetes duration 10.7 (4.8) years, HbA1c 10.2 (0.8)%, or 87 (9.5) mmol/mol at enrollment participated in the interview. Three main themes were identified: (1) improved glycemia despite not using closed loop to its full potential; (2) persistent diabetes burden; and (3) a need for increased psychosocial and clinical support. Although improved glycemia was noted with AHCL therapy, participants reported ongoing motivation issues and used the system suboptimally. They continued to experience distress with overall diabetes management and acknowledged the need for ongoing support from family and health professionals.

Conclusion: All participants reported overall satisfaction with improved glucose levels, however, the persistent diabetes burden impacted their ability to use AHCL optimally. The need for ongoing monitoring with support and interventions to enhance psychological care remains vital for youth with suboptimal diabetes management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016831PMC
http://dx.doi.org/10.1155/2024/6260002DOI Listing

Publication Analysis

Top Keywords

ahcl therapy
16
clinical trial
12
diabetes management
12
experiences youth
8
advanced hybrid
8
hybrid closed-loop
8
therapy clinical
8
ahcl
8
youth suboptimal
8
glucose levels
8

Similar Publications

Management of diabetes mellitus in hemodialysis is highly complex due to increased glycemic variability and hypoglycemic risk. The use of technologies applied to diabetes has been shown to improve glycemic control, however data in dialysis patients are limited. To describe the efficacy and safety of the minimed 780G AHCL system in a stable hemodialysis patient and during hospitalization in the Intensive Care Unit (ICU).

View Article and Find Full Text PDF

Recent advances in automated insulin delivery (AID) system have been remarkable. The advanced hybrid closed-loop (AHCL) system made it easier to achieve optimal glycemic targets. According to previous studies, the AHCL system achieves relatively good glycemic control without strict carbohydrate input.

View Article and Find Full Text PDF

Real-world evaluation of safety and efficacy of AHCL systems in young children with type 1 diabetes: a 1-year assessment.

Front Endocrinol (Lausanne)

July 2025

DINOGMI (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health), University of Genoa, Genoa, Italy.

Background And Aims: Management of Type 1 Diabetes (T1D) in young children is challenging. A poor glycaemic control during the first years of disease increases the risk of microvascular complications. Moreover, hyperglycaemia and glucose variability have a negative effect on the brain development.

View Article and Find Full Text PDF

Background: Hyperglycemia is a major driver of diabetic peripheral neuropathy (DPN) in type 1 diabetes mellitus (T1DM). Advanced hybrid closed-loop (AHCL) technologies improve glycemic control and reduce glycemic variability and may improve DPN.

Methods: Patients with T1DM treated for 9.

View Article and Find Full Text PDF

Pregnancy in people with type 1 diabetes mellitus (T1D) is well-known to be linked to adverse maternal and neonatal outcomes. Although advancements in diabetes technology, especially hybrid closed-loop (HCL) and advanced hybrid closed-loop (AHCL) systems, have greatly enhanced management for nonpregnant individuals with T1D, pregnant patients still represent a high-risk group that requires further research. Existing trials have shown mixed data in terms of clinically meaningful benefits in glycemic control, but these may be specific to the closed-loop system.

View Article and Find Full Text PDF